Olema Pharmaceuticals Inc. (OLMA)
$10.56
$0.13
(1.25%)
As on 01-Sep-2026 16:00EDT
Market cap
$899 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
2.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.5 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-3.3
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-2.1
-
Face value
--
-
Shares outstanding
87,497,607
6 Years Aggregate
CFO
$-241.61 Mln
EBITDA
$-310.15 Mln
Net Profit
$-299.40 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Olema Pharmaceuticals (OLMA)
| -57.8 | -7.8 | -19.9 | 93.4 | 1.3 | -18.8 | -- |
|
BSE Sensex
| -9.1 | -1.5 | 2.9 | -3.6 | 5.9 | 6.0 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Olema Pharmaceuticals (OLMA)
| 328.8 | -58.1 | 472.7 | -73.8 | -80.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Olema Pharmaceuticals (OLMA)
|
10.6 | 898.6 | 0.0 | -204.6 | -- | -45 | -- | 2.2 |
| 82.7 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 71.4 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 56.9 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 107.7 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 363.8 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 538.7 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 583.2 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 353.4 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 146.5 | 9,339.4 | 282.0 | 82.9 | -28.6 | 11.4 | 140.1 | 11.5 |
Shareholding Pattern
View DetailsAbout Olema Pharmaceuticals (OLMA)
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER)... antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 which is in Phase 1 clinical trials for patients with breast and other solid tumor cancers. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California. Read more
-
President, CEO & Director
Dr. Sean P. Bohen M.D., Ph.D.
-
President, CEO & Director
Dr. Sean P. Bohen M.D., Ph.D.
-
Headquarters
San Francisco, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Olema Pharmaceuticals (OLMA)
What is the current share price of Olema Pharmaceuticals Inc (OLMA) Today?
The share price of Olema Pharmaceuticals Inc (OLMA) is $10.56 (NASDAQ) as of 01-Sep-2026 16:00 EDT. Olema Pharmaceuticals Inc (OLMA) has given a return of 1.33% in the last 3 years.
What is the current PB & PE ratio of Olema Pharmaceuticals Inc (OLMA)?
Since, TTM earnings of Olema Pharmaceuticals Inc (OLMA) is negative, P/E ratio is not available.
The P/B ratio of Olema Pharmaceuticals Inc (OLMA) is 2.19 times as on 28-Aug-2026, a 58 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-14.05 |
4.77 |
2024 |
-2.65 |
0.84 |
2023 |
-7.95 |
3.03 |
2022 |
-0.96 |
0.50 |
2021 |
-5.23 |
1.31 |
What is the 52 Week High and Low of Olema Pharmaceuticals Inc (OLMA)?
The 52-week high and low of Olema Pharmaceuticals Inc (OLMA) are Rs 36.26 and Rs 5.36 as of 02-Sep-2026.
What is the market cap of Olema Pharmaceuticals Inc (OLMA)?
Olema Pharmaceuticals Inc (OLMA) has a market capitalisation of $ 899 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Olema Pharmaceuticals Inc (OLMA)?
Before investing in Olema Pharmaceuticals Inc (OLMA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.